BUY Dr. Reddy's Laboratories Limited — Amol Athawale, Kotak Securities
byAmol Athawale, Kotak SecuritiesHorizon: 1–3 months28 Sept 2026via Zee Business (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
MACD above its signal line — bullish momentum
Technicals · macd·28 Sept · today
9 advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days
Advisor consensus · adjacent horizon·28 Sept · today
4 other SEBI-registered advisors have active short-term BUY calls on this stock, with 2 issued in the last 14 days
Advisor consensus · same horizon·21 Sept · 1w ago
Dr. Reddy's Laboratories has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India for Qdenga®, a dengue vaccine, in the private market in India. The agre
BSE · Company Update·18 Sept · 1w ago
JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?
NewsEt-Markets·16 Sept · 2w ago
RSI at 73 — overbought territory
Technicals · rsi·28 Sept · today
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NewsGoogle News·10 Sept · 3w ago
5 advisors have active long-term SELL calls on this stock
Advisor consensus · adjacent horizon·23 Jul · 2mo ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.